Search Results
Showing Results for genetics
Itolizumab, an investigational anti-CD6 monoclonal antibody, has shown promising results in a phase II clinical trial for patients with moderate to severe ulcerative colitis. Designed to target the CD6-ALCAM pathway, a mechanism implicated in gastrointestinal inflammation, itolizumab was reported to achieve clinical remission rates comparable to adalimumab.
This editorial outlines a clinical approach to patients with periodic inflammation of unknown origin despite initial rational and targeted investigation. The focus of the editorial is on the recognition and diagnosis of systemic autoinflammatory diseases (SAIDs). Although rare, SAIDs are ...
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disorder affecting skin, joints, kidneys, the heart, lungs, the brain and blood cells, and is characterized by heterogeneous presentations and severity. It is more common in females than males, with a ratio ...
Fibromyalgia (FM) is defined as widespread musculoskeletal pain and tenderness, in the absence of another explanation. Poor sleep, fatigue and pain are all associated with FM. Diagnostic criteria are well defined,1Â and the prevalence of FM appears to be steadily ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
